CI Earnings Prediction
The chart below shows how CI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CI sees a +0.16% change in stock price 10 days leading up to the earnings, and a -1.39% change 10 days following the report. On the earnings day itself, the stock moves by +0.23%. This data can give you a slight idea of what to expect for the next quarter's release.
CI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
63.69B
29.86%
5.24%
Gross Margin
9.68%
-21.24%
-3.87%
Operating Margin
4.17%
-8.75%
1.96%
Net Margin
1.30%
-55.93%
-51.67%
EPS
2.63
-44.51%
-51.74%
No Data Available
CI Earnings Analysis
The Cigna Group Corporation (CI.N) Earnings Conference Call
Positive
Robust Revenue Performance: 1. Strong Revenue Growth: Cigna Group reported total revenue of $63.7 billion in Q3 2024, reflecting robust performance across its business segments.
Adjusted EPS Growth: 2. Increased Adjusted EPS: The company achieved adjusted earnings per share of $7.51 for the third quarter, contributing to a full-year adjusted EPS outlook of at least $28.40, representing over 13% year-over-year growth.
Evernorth Revenue and Earnings Growth: 3. Evernorth's Performance: Evernorth generated total revenues of $52.5 billion in Q3 2024, with pre-tax adjusted earnings growing 9% to $1.9 billion, driven by strong demand for specialty and care services.
Biosimilar Prescription Transition: 4. Biosimilar Adoption: Approximately one-third of eligible Humira prescriptions transitioned to biosimilars in the quarter, showcasing the successful uptake of innovative therapies that enhance affordability for patients and clients.
Share Repurchase Initiative: 5. Share Repurchase Program: Cigna has repurchased approximately $5.7 billion of its common stock year-to-date, including $715 million in October, demonstrating confidence in its financial strength and commitment to returning value to shareholders.
Negative
Investment Loss Impact: 1. Significant Investment Loss: The Cigna Group reported a non-cash, after-tax net realized investment loss of $1 billion or $3.69 per share related to VillageMD, impacting overall net income negatively.
Special Item Charges Impact: 2. Increased Special Item Charges: The company recorded other after-tax net special item charges of $162 million or $0.58 per share, further detracting from net income.
Rising Medical Expenses: 3. Elevated Medical Costs: The Medicare Advantage market is facing challenges due to elevated medical costs and a significant change in star ratings, contributing to operational disruptions.
Stranded Overhead Costs Impact: 4. Stranded Overhead Costs: Following the sale of the Medicare Advantage business, Cigna anticipates approximately $150 million in stranded overhead costs for 2025, which will impact profitability.
Decreased Net Investment Income: 5. Lower Net Investment Income: The absence of the VillageMD dividend is expected to result in lower net investment income, projected to be a $130 million headwind for 2025.
CI FAQs
How does CI typically perform around its earnings report dates?
Is The Cigna Group (CI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CI Earning Call Sentiment
The Cigna Group (CI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CI.N
4.11%Positive
Despite some headwinds, Cigna's earnings call highlights strong financial performance, including revenue and EPS growth, and a robust share repurchase plan. The Q&A section reveals analysts' interest in specialty growth and strategic investments, with management providing optimistic guidance on future opportunities. While challenges exist, such as the Medicare Advantage market and supply chain issues, the overall sentiment remains positive, bolstered by strong specialty market growth and strategic buybacks.